Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023 17:00 ET
|
Replimune Group Inc
WOBURN, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update
May 18, 2023 08:00 ET
|
Replimune Group Inc
Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma (CSCC) on track for Q3 2023 and...
Replimune to Participate in the Piper Sandler Spring Biopharma Symposium
May 09, 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune to Present at Two Upcoming Investor Conferences
March 08, 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update
February 09, 2023 08:00 ET
|
Replimune Group Inc
Strengthened balance sheet raising gross $259 million through an upsized public offering in December, extending cash runway into H2 2025 and increasing operational and strategic flexibility Topline...
Replimune to Present at the Virtual SVB Securities Global Biopharma Conference
February 07, 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2023 08:05 ET
|
Replimune Group Inc
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer
January 04, 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Announces Pricing of Public Offering
December 08, 2022 21:04 ET
|
Replimune Group Inc
BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...